Guy Jones, MD
Radiation Oncology · Reno, NVNPI 1073824900
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (43.6%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 36 manufacturers reported payments, led by Palette Life Sciences, Inc. at 41.2% of the total. Reporting peaked in 2023 at $24,477 and has fallen 93.2% since, to $1,671 in 2025. Among radiation oncology clinicians in NV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 228 payments — averaging $250.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Palette Life Sciences, Inc.$24K
- Teleflex LLC$21K
- Novocure Inc.$6K
- Varian Medical Systems, Inc.$932
- AbbVie$537
- Telix Pharmaceuticals$518
- plus $5K from 30 others
What the payments were for
- Consulting fees$21,75038%
- Speaking & faculty fees$24,93844%
- Travel & lodging$3,1205%
- Food & beverage$7,20213%
- Education$1990%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Palette Life Sciences, Inc. | 33 | $23,598 |
| Teleflex LLC | 9 | $21,001 |
| Novocure Inc. | 11 | $5,539 |
| Varian Medical Systems, Inc. | 6 | $932 |
| AbbVie | 18 | $537 |
| Telix Pharmaceuticals | 11 | $518 |
| Boston Scientific | 11 | $424 |
| Siemens Medical Solutions USA, Inc. | 8 | $418 |
| Myriad Genetic Laboratories, Inc. | 10 | $366 |
| Progenics Pharmaceuticals, Inc. | 10 | $345 |
| Johnson & Johnson | 3 | $313 |
| Merck | 9 | $279 |
| Isoray, Inc | 4 | $269 |
| Amgen | 10 | $252 |
| Bayer | 13 | $247 |
| E.r. Squibb & Sons, L.L.C. | 5 | $236 |
| Sumitomo Pharma America, Inc. | 6 | $224 |
| Sun Pharmaceutical Industries Inc. | 8 | $213 |
| Novartis | 3 | $173 |
| Blue Earth Diagnostics | 6 | $166 |
| Accord Healthcare, Inc. | 7 | $166 |
| Astellas Pharma US Inc | 4 | $145 |
| Regeneron Healthcare Solutions, Inc. | 4 | $132 |
| Karyopharm Therapeutics Inc. | 1 | $125 |
| Janssen Scientific Affairs, LLC | 1 | $125 |
| Urogen Pharma, Inc. | 3 | $112 |
| Myovant Sciences Inc. | 3 | $61 |
| Mckesson Specialty Care Distribution, LLC | 1 | $51 |
| Angiodynamics, Inc. | 2 | $51 |
| Tactile Systems Technology Inc | 2 | $38 |
| Agiliti Surgical, Inc. | 1 | $37 |
| Koelis Inc. | 1 | $37 |
| Pfizer | 1 | $24 |
| Tolmar Pharmaceuticals, Inc. | 1 | $22 |
| Monteris Medical Corporation | 1 | $20 |
| Merit Medical Systems Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$57,209 in reported general payments places this provider in the 95th percentile of 47 radiation oncology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 11 | $8,682 |
| Tamsulosin Hcl | 154 | $3,268 |
| Pentoxifylline | 11 | $371 |
| SsdSilver Sulfadiazine | 17 | $202 |
| Gabapentin | 14 | $108 |
| Lorazepam | 64 | $93 |
| Ciprofloxacin Hcl | 17 | $44 |
| Alprazolam | 20 | $25 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $145 | $8,68211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 47 radiation oncology providers in Nevada.
Other radiation oncology in Reno
- Garrett GreenReno$37K
- Jason KehrerReno$27K
- Suchit PatelReno$3K
- Lawrence DardickReno$1K
- Michael HardacreReno$850
- Abhinand PeddadaReno$792
- Alexander LinReno$766
- Jaime ShuffReno$648
- Jennifer SuttonReno$405
- Gary CampbellReno$334
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.